Posted by Michael Wonder on 22 Feb 2022
NICE recommends Albireo’s Bylvay (odevixibat) for all PFIC types
22 February 2022 - Positive NICE review completed in less than six months post MHRA approval.
Albireo Pharma today announced that the National Institute for Health and Care Excellence has issued guidance that recommends Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis in people aged six months and older.
